{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:06:57Z","timestamp":1788952017627,"version":"build-2803163510"},"reference-count":60,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clbc.2026.07.026","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T08:51:25Z","timestamp":1784537485000},"page":"91-100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Incidence, Risk Factors, and Survival Implications of Immune-Related Adverse Events in Patients With Metastatic Breast Cancer"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5001-9699","authenticated-orcid":false,"given":"Nikita V.","family":"Baclig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhuri","family":"Chengappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saya","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"LeVee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Fisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyne","family":"Face","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saliha","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dame","family":"Idossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thejaswi","family":"Poonacha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Huppert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Quintal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Melisko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Majure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"Kordic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Mortimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope S.","family":"Rugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa G.","family":"Lechner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Blaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly E.","family":"McCann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2026.07.026_bib0001","unstructured":"U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; https:\/\/www.cdc.gov\/cancer\/dataviz, Accessed: June 2025."},{"issue":"5","key":"10.1016\/j.clbc.2026.07.026_bib0002","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"issue":"3","key":"10.1016\/j.clbc.2026.07.026_bib0003","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.clbc.2026.07.026_bib0004","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and Nab-Paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clbc.2026.07.026_bib0005","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with Immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2026.07.026_bib0006","article-title":"Predictors of severity and onset timing of immune-related adverse events in cancer patients receiving immune checkpoint inhibitors: a retrospective analysis","volume":"16","author":"Fang","year":"2025","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.clbc.2026.07.026_bib0007","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.clbc.2026.07.026_bib0008","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00432-018-2819-x","article-title":"Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma","volume":"145","author":"Indini","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"issue":"24","key":"10.1016\/j.clbc.2026.07.026_bib0009","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1002\/cncr.33780","article-title":"Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors","volume":"127","author":"Foster","year":"2021","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.026_bib0010","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005493","article-title":"Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR\/MSI-H metastatic colorectal cancer","volume":"11","author":"Nasca","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.026_bib0011","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.52302","article-title":"Immune-related adverse events and survival among patients with metastatic NSCLC treated with immune checkpoint inhibitors","volume":"7","author":"Cook","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"18","key":"10.1016\/j.clbc.2026.07.026_bib0012","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14184369","article-title":"Management of immune-related adverse events from Immune-checkpoint inhibitors in advanced or metastatic renal cell carcinoma","volume":"14","author":"Leucht","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clbc.2026.07.026_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.633032","article-title":"Association of immune related adverse events with efficacy of immune checkpoint inhibitors and overall survival in cancers: a systemic review and meta-analysis","volume":"11","author":"Fan","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.026_bib0014","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12916-020-01549-2","article-title":"Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis","volume":"18","author":"Zhou","year":"2020","journal-title":"BMC Med"},{"key":"10.1016\/j.clbc.2026.07.026_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102134","article-title":"Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors \u2013 a systematic review and meta-analysis","volume":"92","author":"Hussaini","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clbc.2026.07.026_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102787","article-title":"The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"129","author":"Zhang","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clbc.2026.07.026_bib0017","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejca.2020.03.017","article-title":"Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors","volume":"132","author":"Maillet","year":"2020","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.026_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0000000000000300","article-title":"Immune-related adverse events and survival in solid tumors treated with Immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"43","author":"Petrelli","year":"2020","journal-title":"J Immunother"},{"issue":"12","key":"10.1016\/j.clbc.2026.07.026_bib0019","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.45596","article-title":"Association of immune-related adverse events, hospitalization, and therapy resumption with survival among patients with metastatic melanoma receiving single-agent or combination immunotherapy","volume":"5","author":"Watson","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clbc.2026.07.026_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108555","article-title":"Impact of immune-related adverse event severity on overall survival in patients with advanced NSCLC receiving immune checkpoint inhibitors therapy, with a focus on combination regimens","volume":"204","author":"Sugai","year":"2025","journal-title":"Lung Cancer"},{"issue":"15","key":"10.1016\/j.clbc.2026.07.026_bib0021","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70080","article-title":"Evaluation of the association between predictive factors and the development of immune-related adverse events and prognostic factors for chemoimmunotherapy in patients with non-small cell lung cancer: a multicenter retrospective study","volume":"13","author":"Ozawa","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.clbc.2026.07.026_bib0022","doi-asserted-by":"crossref","DOI":"10.1177\/10732748221130576","article-title":"A retrospective cohort study of multiple immune-related adverse events and clinical outcomes among patients with cancer receiving immune checkpoint inhibitors","volume":"29","author":"Hata","year":"2022","journal-title":"Cancer Control"},{"key":"10.1016\/j.clbc.2026.07.026_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104635","article-title":"Clinical benefit of immune checkpoint inhibitors in elderly cancer patients: current evidence from immunosenescence pathophysiology to clinical trial results","volume":"208","author":"Ziogas","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clbc.2026.07.026_bib0024","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejca.2020.01.013","article-title":"Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies","volume":"129","author":"Baldini","year":"2020","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.026_bib0025","doi-asserted-by":"crossref","DOI":"10.1093\/ageing\/afaf008","article-title":"Immune-related adverse events in older adults receiving immune checkpoint inhibitors: a comprehensive analysis of the Food and Drug Administration Adverse Event Reporting System","volume":"54","author":"Esen","year":"2025","journal-title":"Age Ageing"},{"key":"10.1016\/j.clbc.2026.07.026_bib0026","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.breast.2022.07.006","article-title":"Progression-free survival and quality of life in metastatic breast cancer: the patient perspective","volume":"65","author":"Mertz","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2026.07.026_bib0027","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","year":"2017"},{"key":"10.1016\/j.clbc.2026.07.026_bib0028","unstructured":"Stata Statistical Software: Release 15. 2017."},{"issue":"1","key":"10.1016\/j.clbc.2026.07.026_bib0029","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41523-025-00849-1","article-title":"Multi-institutional analysis of incidence and risks for late-onset immune toxicity in breast cancer","volume":"11","author":"Jacob","year":"2025","journal-title":"NPJ Breast Cancer"},{"issue":"21","key":"10.1016\/j.clbc.2026.07.026_bib0030","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","article-title":"Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study","volume":"34","author":"Nanda","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.07.026_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107796","article-title":"Adverse events associated with immune checkpoint inhibitors in patients with breast cancer: a systematic review and meta-analysis","volume":"96","author":"Balibegloo","year":"2021","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"10.1016\/j.clbc.2026.07.026_bib0032","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/S1470-2045(24)00528-X","article-title":"Effectiveness and safety of immune checkpoint inhibitors in Black patients versus White patients in a US national health system: a retrospective cohort study","volume":"25","author":"Miller","year":"2024","journal-title":"Lancet Oncol"},{"issue":"16_suppl","key":"10.1016\/j.clbc.2026.07.026_bib0033","article-title":"Racial differences in serious immune-related adverse events among cancer patients receiving immune checkpoint inhibitors","volume":"43","author":"Chiang","year":"2025","journal-title":"JCO"},{"issue":"16_suppl","key":"10.1016\/j.clbc.2026.07.026_bib0034","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.e21115","article-title":"Impact of ethnicity and immune-related adverse events (Irae) on outcomes for non-small cell lung cancer (Nsclc) patients treated with immune checkpoint inhibitors","volume":"40","author":"Resnick","year":"2022","journal-title":"JCO"},{"issue":"3","key":"10.1016\/j.clbc.2026.07.026_bib0035","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae279","article-title":"The impact of immune-related adverse events on survival outcomes in a racially diverse population, with a focus on non-Hispanic black patients","volume":"30","author":"Radwan","year":"2025","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.clbc.2026.07.026_bib0036","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1158\/1055-9965.EPI-24-0333","article-title":"Evaluation of the immune response within the tumor microenvironment in African American and Non-Hispanic white patients with Non-small cell lung cancer","volume":"33","author":"Trendowski","year":"2024","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"16_suppl","key":"10.1016\/j.clbc.2026.07.026_bib0037","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.9549","article-title":"Determinants of racial disparities in immune-related adverse events (IRAE) with checkpoint inhibition (ICI) in melanoma","volume":"41","author":"Ibrahim","year":"2023","journal-title":"JCO"},{"issue":"20","key":"10.1016\/j.clbc.2026.07.026_bib0038","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.2217\/fon-2020-0861","article-title":"Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data","volume":"17","author":"Shimozaki","year":"2021","journal-title":"Future Oncol"},{"issue":"15","key":"10.1016\/j.clbc.2026.07.026_bib0039","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14153736","article-title":"Peripheral blood biomarkers predictive of efficacy outcome and immune-related adverse events in advanced gastrointestinal cancers treated with checkpoint inhibitors","volume":"14","author":"Zhang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clbc.2026.07.026_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.clon.2024.10.034","article-title":"Immune-related and common adverse events with programmed cell death 1\/programmed cell death ligand 1 inhibitors combined with other anticancer therapy for solid tumors: a systematic review and meta-analysis","volume":"37","author":"Inoue","year":"2025","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"35","key":"10.1016\/j.clbc.2026.07.026_bib0041","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.18632\/oncotarget.26908","article-title":"Comparative safety analysis of immunotherapy combined with chemotherapy versus monotherapy in solid tumors: a meta-analysis of randomized clinical trials","volume":"10","author":"Carretero-Gonz\u00e1lez","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.clbc.2026.07.026_bib0042","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41523-022-00482-2","article-title":"Abemaciclib in combination with pembrolizumab for HR+, HER2\u2212 metastatic breast cancer: phase 1b study","volume":"8","author":"Rugo","year":"2022","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.clbc.2026.07.026_bib0043","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejca.2021.05.035","article-title":"Phase I\/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer","volume":"154","author":"Yuan","year":"2021","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.clbc.2026.07.026_bib0044","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41577-020-0300-y","article-title":"Immunomodulation by anticancer cell cycle inhibitors","volume":"20","author":"Petroni","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10.1016\/j.clbc.2026.07.026_bib0045","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf123","article-title":"Pre-existing and emerging immune-mediated diseases in patients with breast cancer undergoing cyclin-dependent kinases 4\/6 inhibitors and endocrine therapy","volume":"30","author":"Jacobs","year":"2025","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.clbc.2026.07.026_bib0046","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.clbc.2026.07.026_bib0047","article-title":"Immune checkpoint inhibitors plus platinum-based chemotherapy compared to platinum-based chemotherapy with or without bevacizumab for first-line treatment of older people with advanced non-small cell lung cancer","author":"Orillard","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.clbc.2026.07.026_bib0048","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S1470-2045(24)00278-X","article-title":"Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study","volume":"25","author":"Wan","year":"2024","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.clbc.2026.07.026_bib0049","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41591-024-03415-7","article-title":"Pembrolizumab and chemotherapy in high-risk, early-stage, ER+\/HER2- breast cancer: a randomized phase 3 trial","volume":"31","author":"Cardoso","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.clbc.2026.07.026_bib0050","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41591-024-03414-8","article-title":"Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial","volume":"31","author":"Loi","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.clbc.2026.07.026_bib0051","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1200\/JCO.23.01940","volume":"42","author":"Mayer","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clbc.2026.07.026_bib0052","doi-asserted-by":"crossref","first-page":"394","DOI":"10.18632\/oncotarget.27877","article-title":"Tumor mutational burden as a predictor of immunotherapy response in breast cancer","volume":"12","author":"O'Meara","year":"2021","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.clbc.2026.07.026_bib0053","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.annonc.2019.11.010","article-title":"Prevalence and mutational determinants of high tumor mutation burden in breast cancer","volume":"31","author":"Barroso-Sousa","year":"2020","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.clbc.2026.07.026_bib0054","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1001\/jama.2024.3056","article-title":"Tumor-infiltrating lymphocytes in triple-negative breast cancer","volume":"331","author":"Leon-Ferre","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.026_bib0055","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.clbc.2026.07.026_bib0056","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41568-020-0281-y","article-title":"Neutrophil diversity and plasticity in tumour progression and therapy","volume":"20","author":"Jaillon","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clbc.2026.07.026_bib0057","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01778","article-title":"Neutrophils: orchestrators of the malignant phenotype","volume":"11","author":"Hsu","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.clbc.2026.07.026_bib0058","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1228076","article-title":"The neutrophil-to-lymphocyte ratio as a new prognostic factor in cancers: a narrative review","volume":"13","author":"Heshmat-Ghahdarijani","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.clbc.2026.07.026_bib0059","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01940","article-title":"The obesity paradox in cancer, tumor immunology, and immunotherapy: potential therapeutic implications in triple negative breast cancer","volume":"10","author":"Naik","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.clbc.2026.07.026_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113699","article-title":"Explanation of the obesity paradox of immunotherapy in cancer patients using CT-derived adipose composition parameters: a systematic review and meta-analysis","volume":"144","author":"Lou","year":"2025","journal-title":"Int Immunopharmacol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926001266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926001266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:08:22Z","timestamp":1788948502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820926001266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":60,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1526820926001266"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2026.07.026","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence, Risk Factors, and Survival Implications of Immune-Related Adverse Events in Patients With Metastatic Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2026.07.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}